An Analytical Hierarchy Process (AHP) Approach to Risk Analysis: A Case Study of a New Generic Drug Development Process
- 348 Downloads
Risks that are associated with the new generic drug development process, which is the initial stage of the pharmaceutical supply chain, need to be considered and eliminated. The main purpose of this study was to prioritize the risks associated with the new generic drug development process in Thailand.
In this study, an in-depth interview, several rounds of expert discussion, and a focus group have been conducted to identify the risk factors. The final analysis was summarized based on the analytic hierarchy process (AHP) methodology.
The risks were classified into the following seven categories: (1) regulatory, (2) technological, (3) operational, (4) intellectual property, (5) financial, (6) market, and (7) information. They were used as criteria for and developed a questionnaire according to the AHP structure. The results from the inputs of ten experts in the pharmaceutical supply chain who identified the priority criteria among these seven categories revealed that the most important criterion is regulatory risk, followed by information, operational, financial, intellectual property, market, and technology risks.
These major risks should be prioritized so that they can be appropriately managed.
KeywordsNew generic drug Pharmaceutical supply chain Supply chain risk management (SCRM) Analytic hierarchy process (AHP)
Acknowledgement and Funding
This research is supported by the National Research Council of Thailand (NRCT) under the graduated research scholarship in the year 2016. The authors would like to acknowledge the representatives from local pharmaceutical companies and other involved parties who participated in the preliminary study’s in-depth interview, as well as experts from the pharmaceutical industry and academic who provided their opinions for a pair-wise comparison in the analytic hierarchy process (AHP) analysis in this research.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 1.The Government Pharmaceutical Organization. Annual Report. 2012. http://www.gpo.or.th/LinkClick.aspx?fileticket=9xPrsy1J8hI%3d&tabid=96&mid=470. Accessed 8 June 2013.
- 3.Merna T, Al Thani FF. Case study 1: Risks in projects in the pharmaceutical industry. Corporate risk management. 2nd ed. USA: Wiley; 2008. p. 319–32.Google Scholar
- 11.Thailand Board of Investment. Thailand Invest Rev. 2011;21(8). http://www.boi.go.th/english/download/e_newsletter/91/August_11.htm. Accessed 21 July 2014.
- 12.Thailand Board of Investment. Investment Promot J. 2016;27(4). http://www.boi.go.th/upload/content/BOI-April2016_82702.pdf. Accessed 10 Aug 2016.
- 13.Enyinda CI. Modelling risk management in the pharmaceutical industry global supply chain logistics using analytical hierarchy process model (Doctoral dissertation). Fargo: North Dakota State University of Agriculture and Applied Science; 2008.Google Scholar
- 15.KPMG International. Risk management in the pharmaceuticals and life sciences industry: an economist intelligence unit research program. 2009. https://www.eiuperspectives.economist.com/sites/default/files/Risk%20management%20in%20the%20pharmaceuticals%20and%20life%20sciences%20industry.pdf. Accessed 8 Oct 2016.
- 17.The Chartered Quality Institute. A guide to supply chain risk management for the pharmaceutical and medical device industries and their suppliers. 2010. http://www.pqg.org/download-files/PQG-Guide-to-Supply-Chain-Risk-Management-V-1-0-2010.pdf. Accessed 8 Jan 2013.